Targeting the BH3 domain of Bcl-2 family proteins. A brief history from natural products to foldamers as promising cancer therapeutic avenues.

@article{Giorgi2013TargetingTB,
  title={Targeting the BH3 domain of Bcl-2 family proteins. A brief history from natural products to foldamers as promising cancer therapeutic avenues.},
  author={Mattia De Giorgi and Anne Sophie Voisin-Chiret and Sylvain Rault},
  journal={Current medicinal chemistry},
  year={2013},
  volume={20 24},
  pages={
          2964-78
        }
}
For many years the spotlight in drug discovery has been on a relatively small number of validated therapeutic target classes, such as G-protein coupled receptors and enzymes such as protein kinases, with well characterized enzymatic and cellular activities. However, with recent progress in genomics and proteomics, protein-protein interactions (PPIs) provide… CONTINUE READING